DUALOP
Development of a dual-action molecule for the treatment of chronic and acute pain.
Project description
This project concerns the development of a dual-action molecule representing an innovative strategy for developing new opioid analgesics with fewer side effects than conventional opioids and thus meeting a real market need.
Why does Conectus invest in this project?
Conectus' financial investment will optimize the chemical series identified by the research team and provide the in vitro and in vivo proof of concept necessary to demonstrate the compound's potential in the treatment of pain.
At the origin of the project:
SIMONIN Frédéric, UMR7242/Biotechnology and cellular signal, and Frédéric BIHEL (Therapeutic Innovation Laboratory) UMR 7200 CNRS - Unistra
Focus
Conectus investit sur ce projet : 450 000 €
Durée : 18 mois